PSMA配体摄取可作为原发性前列腺癌根治术后预后预测的新型生物标志物
该回顾性研究纳入186例根治术前3个月内行68Ga-PSMA-11 PET的原发性前列腺癌患者,基于miTNM框架建立PET分期系统。中位随访38个月,58例出现生化复发;miT状态、PSA水平和高级别Gleason评分是BCR的独立预测因子,PET分期I期中SUVmax较高者无BCR生存更短。
要点
- 术前68Ga-PSMA-11 PET的miTNM分类与术后Gleason评分、手术切缘状态及BCR时间相关。
- miT≥3a、PSA水平和Gleason评分≥8是BCR的独立预测因子。
- PET分期I期中SUVmax较高者无BCR生存更短。
核心结论
- 术前68Ga-PSMA-11 PET的miTNM分类与术后Gleason评分、手术切缘状态和BCR时间相关,提示其可作为新型无创影像生物标志物用于治疗前辅助分层。
研究设计与样本
- 回顾性分析纳入186例接受根治性前列腺切除术且术前3个月内行68Ga-PSMA-11 PET的原发性前列腺癌患者。
- 收集PET影像的SUVmax、SUVmean、肿瘤体积和总病灶,以及年龄、血清PSA和病理特征等临床病理信息。
- 基于miTNM框架开发PET影像分期的分期组系统。
主要发现
- 根治术后中位随访38个月(IQR 22-53),随访期间58例患者出现生化复发。
- 手术切缘阳性与miN状态(miN1 vs. miN0)显著相关(OR:5.428,p=0.004)。
- miT状态(miT≥3a vs. miT<3)是Gleason评分≥8的独立预测因子(OR:2.696,p=0.003)。
- 多因素Cox回归显示PSA水平(HR:1.024,p=0.014)、高级别Gleason评分(GS≥8 vs. GS<8,HR:3.253,p<0.001)和miT状态(miT≥3a vs. miT<3,HR:1.941,p=0.035)是BCR的独立预测因子。
- PET影像确定的I期疾病中,较高SUVmax患者(IA vs. IB期)的无BCR生存更短(log-rank,p=0.022)。
临床怎么用
- 术前68Ga-PSMA-11 PET的miTNM分类可用于辅助预测根治术后Gleason评分、切缘状态和BCR风险。
- 对于PET分期I期患者,SUVmax较高提示无BCR生存较短,可考虑辅助治疗前分层。
局限性
- 本文为回顾性分析,样本来自单中心,结论需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prostate-specific membrane antigen (PSMA) is a relevant target in prostate cancer, and immunohistochemistry studies showed associations with outcome. PSMA-ligand positron emission tomography (PET) is increasingly used for primary prostate cancer staging, and the molecular imaging TNM classification (miTNM) standardizes its reporting. We aimed to investigate the potential of PET-imaging to serve as a noninvasive imaging biomarker to predict disease outcome in primary prostate cancer after radical prostatectomy (RP). METHODS: In this retrospective analysis, 186 primary prostate cancer patients treated with RP who had undergone a 68Ga-PSMA-11 PET up to three months prior to the surgery were included. Maximum standardized uptake value (SUVmax), SUVmean, tumor volume (TV) and total lesion (TL) were collected from PET-imaging. Moreover, clinicopathological information, including age, serum prostate-specific antigen (PSA) level, and pathological characteristics, was assessed for disease outcome prediction. A stage group system for PET-imaging findings based on the miTNM framework was developed. RESULTS: At a median follow-up after RP of 38 months (interquartile range (IQR) 22-53), biochemical recurrence (BCR) was observed in 58 patients during the follow-up period. A significant association between a positive surgical margin and miN status (miN1 vs. miN0, odds ratio (OR): 5.428, p = 0.004) was detected. miT status (miT ≥ 3a vs. miT < 3, OR: 2.696, p = 0.003) was identified as an independent predictor for Gleason score (GS) ≥ 8. Multivariate Cox regression analysis indicated that PSA level (hazard ratio (HR): 1.024, p = 0.014), advanced GS (GS ≥ 8 vs. GS < 8, HR: 3.253, p < 0.001) and miT status (miT ≥ 3a vs. miT < 3, HR: 1.941, p = 0.035) were independent predictors for BCR. For stage I disease as determined by PET-imaging, a shorter BCR-free survival was observed in the patients with higher SUVmax (IA vs. IB stage, log-rank, p = 0.022). CONCLUSION: Preoperative miTNM classification from 68Ga-PSMA-11 PET correlates with postoperative GS, surgical margin status and time to BCR. The association between miTNM staging and outcome proposes 68Ga-PSMA-11 PET as a novel non-invasive imaging biomarker and potentially serves for ancillary pre-treatment stratification.
引用
- Wang H, Amiel T, Würnschimmel C, et al. PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy. EJNMMI Res. 2021. PMID: 34417907. doi:10.1186/s13550-021-00818-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。